Merck KGaA (OTCMKTS:MKGAF) Shares Gap Up – Should You Buy?

Merck KGaA (OTCMKTS:MKGAF)’s share price gapped up prior to trading on Tuesday. The stock had previously closed at $157.9690, but opened at $167.1350. Merck KGaA shares last traded at $167.5490, with a volume of 84 shares traded.

Merck KGaA Price Performance

The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The firm’s fifty day moving average is $159.57 and its two-hundred day moving average is $153.99. The company has a market cap of $21.77 billion, a P/E ratio of 25.72 and a beta of 0.96.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Elefante Mark B purchased a new stake in shares of Merck KGaA in the 2nd quarter valued at about $617,000. Ames National Corp acquired a new position in shares of Merck KGaA during the 2nd quarter valued at $1,009,000. Notis McConarty Edward acquired a new stake in Merck KGaA during the 2nd quarter valued at approximately $1,304,000. North Star Asset Management Inc. bought a new stake in Merck KGaA during the second quarter valued at $1,411,000. Finally, Pinnacle Holdings LLC bought a new stake in Merck KGaA in the 2nd quarter valued at about $1,487,000. Hedge funds and other institutional investors own 0.10% of the company’s stock.

About Merck KGaA

Merck KGaA is a German science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The company operates under the name EMD Serono in the United States and Canada, where the Merck name is associated with a separate company.

Merck KGaA operates through three primary business sectors: Healthcare, Life Science and Electronics. Its Healthcare business develops and markets prescription medicines, including treatments in oncology, neurology and immunology, as well as fertility and other specialty-care products.